(Circulation. 2000;101:1097.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Aspirin Use Is Low Among United States Outpatients With Coronary Artery Disease
From the Institute for Health Policy and General Medicine Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Randall S. Stafford, MD, PhD, Institute for Health Policy, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114. E-mail rstafford{at}partners.org
Background—The goal of the present study was to assess national trends and patterns of aspirin use among outpatients with coronary artery disease. Although there is strong evidence that the use of aspirin reduces the risk of death and recurrent events in patients with coronary artery disease, current national patterns of aspirin use are unknown.
Methods and Results—We used data from the 1980 to 1996 National
Ambulatory Medical Care Surveys. These surveys provide a nationally
representative sample of physician activities during
patient visits to physician offices. We evaluated the report of aspirin
as a new or continuing medication in 10 942 visits to cardiologists
and primary care physicians by patients with coronary artery
disease. We evaluated trends in the use of aspirin for 1980 to 1996 and
used logistic regression to identify independent predictors of aspirin
use for 1993 to 1996. Aspirin use in outpatient visits by persons with
coronary artery disease without reported contraindications
increased from 5.0% in 1980 to 26.2% in 1996. Large increases
occurred in the early 1990s. Independent predictors of aspirin use in
1993 to 1996 were male patient gender (29% versus 21% for females),
patient age of <80 years (28% versus 17% for age of 
80 years), and
presence of hyperlipidemia (45% versus 24% for
patients without hyperlipidemia; all comparisons
P<0.001). Cardiologists (37%) were more likely to
report aspirin use than were internists (20%), family physicians
(18%), or general practitioners (11%;
P<0.001). These effects persisted after we controlled
for potential confounders with the use of logistic regression.
Conclusions—Although aspirin use in patients with coronary artery disease has increased dramatically, it remains suboptimum. Low rates of aspirin use and variations in use suggest a need to better translate clinical recommendations into practice.
Key Words: aspirin • heart diseases • prevention
This article has been cited by other articles:
 |
|
 |
|
  S. Keyhani, J. V. Scobie, P. L. Hebert, and M. A. McLaughlin Gender Disparities in Blood Pressure Control and Cardiovascular Care in a National Sample of Ambulatory Care Visits Hypertension, April 1, 2008; 51(4): 1149 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Stirban and D. Tschoepe Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? Diabetes Care, February 1, 2008; 31(Supplement_2): S226 - S228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Shaw, C. N. Bairey Merz, C. J. Pepine, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, S. Mankad, B. L. Sharaf, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S4 - S20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Bairey Merz, L. J. Shaw, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, C. J. Pepine, S. Mankad, B. L. Sharaf, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S21 - S29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lappe, J. B. Muhlestein, D. L. Lappe, R. S. Badger, T. L. Bair, R. Brockman, T. K. French, L. C. Hofmann, B. D. Horne, S. Kralick-Goldberg, et al. Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program Ann Intern Med, September 21, 2004; 141(6): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Patel and K. C. Goldberg Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction Arch Intern Med, April 26, 2004; 164(8): 852 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnicka, et al. Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology Eur. Heart J., January 2, 2004; 25(2): 166 - 181. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Stafford and D. C. Radley The underutilization of cardiacmedications of proven benefit, 1990 to 2002 J. Am. Coll. Cardiol., January 1, 2003; 41(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Weisman and D. Y. Graham Evaluation of the Benefits and Risks of Low-Dose Aspirin in the Secondary Prevention of Cardiovascular and Cerebrovascular Events Arch Intern Med, October 28, 2002; 162(19): 2197 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Gaspoz, P. G. Coxson, P. A. Goldman, L. W. Williams, K. M. Kuntz, M.G. M. Hunink, and L. Goldman Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease N. Engl. J. Med., June 6, 2002; 346(23): 1800 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.J. Wood When Increased Therapeutic Benefit Comes at Increased Cost N. Engl. J. Med., June 6, 2002; 346(23): 1819 - 1821. [Full Text] [PDF]
|
|
|
|
|
|
S. I. McFarlane, S. J. Jacober, N. Winer, J. Kaur, J. P. Castro, M. A. Wui, A. Gliwa, H. Von Gizycki, and J. R. Sowers Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers Diabetes Care, April 1, 2002; 25(4): 718 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Brown, T. E. Delea, G. A. Nichols, J. Edelsberg, P. J. Elmer, and G. Oster Use of Oral Antithrombotic Agents Among Health Maintenance Organization Members With Atherosclerotic Cardiovascular Disease Arch Intern Med, January 28, 2002; 162(2): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ, January 12, 2002; 324(7329): 71 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Marchioli, F Avanzini, F Barzi, C Chieffo, A Di Castelnuovo, M.G Franzosi, E Geraci, A.P Maggioni, R.M Marfisi, N Mininni, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations; GISSI-Prevenzione mortality risk chart Eur. Heart J., November 2, 2001; 22(22): 2085 - 2103. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-D. Beaulieu, R. Blais, A. Jacques, R.N. Battista, R. Lebeau, and J. Brophy Are patients suffering from stable angina receiving optimal medical treatment? QJM, June 1, 2001; 94(6): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Rolka, A. Fagot-Campagna, and K.M. V. Narayan Aspirin Use Among Adults With Diabetes: Estimates from the Third National Health and Nutrition Examination Survey Diabetes Care, February 1, 2001; 24(2): 197 - 201. [Abstract] [Full Text]
|
|
|
|
 |
|
 Low Aspirin Use in Outpatients with CAD Journal Watch Women's Health, May 1, 2000; 2000(501): 2 - 2. [Full Text]
|
|